Skip to main content
Clinical Trials/NCT03481608
NCT03481608CompletedNot Applicable

Production of a LRH-1 Ligand in Humans: A Randomized,Controlled, Cross-Over Feeding Trial

Cornell University1 site in 1 country10 target enrollmentStarted: March 19, 2018Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
10
Locations
1
Primary Endpoint
DLPC in Postprandial Serum

Study Overview

Brief Summary

A phosphatidylcholine species enriched with lauric acid at both the sn-1 and sn-2 positions, dilauroylphosphatidylcholine (DLPC), was recently identified as a ligand for the nuclear receptor, liver receptor homolog-1 (LRH-1). To date, DLPC has not been reported in vitro or in vivo, and has yet to be catalogued in the human metabolomics database. This intervention trial aims to determine the impact of consumption of dietary lauric acid, in the form of coconut oil (49% lauric acid), can facilitate the production of DLPC in humans.

Detailed Description

A phosphatidylcholine species enriched with lauric acid at both the sn-1 and sn-2 positions, dilauroylphosphatidylcholine (DLPC), was recently identified as a ligand for the nuclear receptor, liver receptor homolog-1 (LRH-1). LRH-1 has notable roles in regulating sterol metabolism, with downstream impacts on reproductive capacity, bile acid production, glucose metabolism, and cell proliferation. Manipulation of LRH-1 activity via ligand-inducing binding and activation has the potential to act as a therapy in certain metabolic disorders, such as type 2 diabetes. To date, the LRH-1 ligand, DLPC, has not been reported in vitro or in vivo, and has yet to be indexed in the Human Metabolomics Database, suggesting that it's therapeutic potential is limited to pharmacological administration. The investigators' forthcoming unpublished research tested the hypothesis that the lack of DLPC in physiological systems results from substrate insufficiency, and have observed that consumption of dietary lauric acid facilitates the production of DLPC in animal models, and addition of lauric acid to the culture media of cells additionally leads to its production. A single acute gavage of coconut oil results in the production of DLPC in the intestine and export in the serum 1-2 hours post-gavage. To extend this work to humans, the investigators are undertaking an acute, randomized, cross-over trial of dietary lauric acid consumption. This intervention trial aims to determine whether dietary lauric acid, in the form of coconut oil (49% lauric acid), can facilitate the production of DLPC in humans. The investigators have hypothesized that consumption of a single breakfast shake containing coconut oil will result in DLPC in post-prandial serum. Participants will be invited to the Cornell University Human Metabolic Research Unit (HMRU) on 2 separate occasions to consume 1 of 2 breakfast shake , delivered in random order. Shakes will be made with either 2 tablespoons of olive oil (control) or coconut oil (intervention). Participants will arrive to the HMRU fasted and provide a baseline blood sample, prior to consumption of the breakfast shake ; at 2, 4, and 6 hours following the meal, participants will provide additional blood samples. Prior to and throughout the duration of the study, participants will be asked to avoid consumption of tropical oils. Lauric acid is typically a minimal component of the common diet, though substantial intakes can occur with the consumption of tropical oils, such as coconut oil or palm kernel oil. Lauric acid is considered one of the three primary hypercholesterolemic saturated fatty acids and is currently not recommended to constitute a major component of the diet; participants for whom a cholesterol lowering diet is recommended will not be able to enroll in the study.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Crossover
Primary Purpose
Basic Science
Masking
Single (Participant)

Masking Description

Participants will be blinded to the intervention oil (single-blind).

Eligibility Criteria

Ages
18 Years to 50 Years (Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •Willingness to comply with the study protocol
  • •Ability to overnight fast
  • •Willingness to donate blood
  • •'generally healthy'

Exclusion Criteria

  • •self-reported regular consumption of tropical oils or supplements containing lauric acid
  • •self-reported food allergies to shake ingredients
  • •medical conditions where blood draws or fasting may be contraindicated
  • •major gastrointestinal conditions, such as inflammatory bowel disease

Arms & Interventions

Olive Oil Shake

Active Comparator

Intervention: No Lauric Acid

A breakfast shake made from a complete meal shake will be prepared with water and supplemented with 2 tablespoons of olive oil.

Intervention: No Lauric acid (olive oil) (Other)

Coconut Oil Shake

Experimental

Intervention: Lauric Acid

A breakfast shake made from a complete meal shake will be prepared with water and supplemented with 2 tablespoons of coconut oil.

Intervention: Lauric acid (coconut oil) (Other)

Outcomes

Primary Outcomes

DLPC in Postprandial Serum

Time Frame: 6 hours postprandial

The presence of DLPC in postprandial serum will be measured using Liquid Chromatography Tandem Mass Spectrometry

Secondary Outcomes

  • Serum Total Bile Acids(6 hours postprandial)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials

Recruiting
Phase 3
Detection of recombinant human luteinising hormone (rLH) as a doping agentSports doping detectionMetabolic and Endocrine - Normal metabolism and endocrine development and function
ACTRN12608000181303Sydney South Western Area Health Service (SSWAHS)64
Completed
Phase 4
Nordic Luveris StudyIn Vitro FertilizationInfertility
NCT00553293Rigshospitalet, Denmark526
Completed
Phase 1
Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic SyndromeRefractory Anemia With Excess Blasts in TransformationRelapsing Chronic Myelogenous LeukemiaAccelerated Phase Chronic Myelogenous LeukemiaAdult Acute Myeloid Leukemia in RemissionChronic Phase Chronic Myelogenous LeukemiaPreviously Treated Myelodysplastic SyndromesRefractory Anemia With Excess Blasts
NCT00004918National Cancer Institute (NCI)69
Completed
Phase 4
Menopausal transition and prospects of treatmentReproductive Health and Childbirth - Menstruation and menopauseAlternative and Complementary Medicine - Other alternative and complementary medicineMetabolic and Endocrine - Normal metabolism and endocrine development and functionmenopauseclimacteric syndrome
ACTRN12611000200987niversidade Federal do Rio Grande do Norte200
Completed
Not Applicable
Preliminary study on recombinant human soluble thrombomodulin (rTM) administration for treatment of pneumonia-induced acute respiratory distress syndrome (ARDS) complicated with disseminated intravascular coagulation(DIC) and sepsis, including avian influenza virus infectioPneumonia-induced acute respiratory distress syndrome (ARDS) complicated with disseminated intravascular coagulation(DIC) and sepsis, including avian influenza virus infection
JPRN-UMIN000020358ational Hospital for Pediatrics, Nanoi, Vietnam3